Insiders who bought US$82.3k worth of Regulus Therapeutics Inc.'s ( NASDAQ:RGLS ) stock at an average buy price ...

Shares of Regulus Therapeutics ( RGLS, Financials) fell 24% to $0.89 as of 12:39 p.m. GMT-5 on Wednesday following the ...

Regulus Therapeutics Inc.’s RGLS share price has dipped by 17.09%, which has investors questioning if this is right time to ...

Regulus Therapeutics (RGLS) shares tumbled 24% after the company reported results from a study analysis for its ADPKD program and issued a regulatory update. Read more here.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regulus (RGLS – Research Report) and Roche ...

(RTTNews) - Regulus Therapeutics Inc. (RGLS) Wednesday announced positive clinical as well as regulatory updates from its autosomal dominant polycystic kidney disease (ADPKD) program.

Regulus Therapeutics Inc (RGLS) stock saw a decline, ending the day at $0.97 which represents a decrease of $-0.20 or -17.09% from the prior close of $1.17. The stock opened at $1.08 and touched a low ...

February stargazing is fantastic for many reasons, but this year there’s a one-two-three punch of bright planets adding to ...

In an indication that has proved difficult for biopharma to conquer, Regulus Therapeutics Inc. disclosed further positive data from its ongoing phase Ib study testing RGLS-8429 in autosomal dominant ...

By Sandra Agyeiwaa OTOO Management of Business and Financial Times (B&FT), Africa’s leading business news provider, has paid a courtesy call to Regulus Investment and Financial Services Limited, Ghana ...

Exciting February sky events include Venus at its brightest and closest to Earth, the moon occulting the Pleiades, and a parade of planets in the post-sunset sky.

Regulus Therapeutics Inc . (NASDAQ:RGLS) stock has reached a new 52-week low, touching down at $1.16. This latest price ...